Procept Biorobotics Stock Price, News & Analysis

PROCEPT BioRobotics Corporation (Nasdaq: PRCT) is a surgical robotics company focused on advancing patient care in urology. According to the company, its mission is to revolutionize treatment for benign prostatic hyperplasia (BPH) in partnership with urologists by delivering robotic systems that positively impact patients and drive value. PROCEPT BioRobotics develops and manufactures the AQUABEAM and HYDROS Robotic Systems, which are designed to deliver Aquablation therapy, a minimally invasive approach for males suffering from lower urinary tract symptoms (LUTS) due to BPH.

Core business and technology focus

The company describes itself as a surgical robotics business dedicated to "transformative solutions in urology." Its primary focus is on BPH, which it identifies as the most common prostate disease, impacting approximately 40 million men in the United States. PROCEPT BioRobotics states that the HYDROS Robotic System is the only AI-powered robotic technology that delivers Aquablation therapy. Aquablation therapy is designed to provide effective, safe, and durable outcomes that are independent of prostate size and shape or surgeon experience.

PROCEPT BioRobotics reports that it has built a significant and growing body of clinical evidence supporting Aquablation therapy, with over 150 peer-reviewed publications cited in company materials as demonstrating benefits and clinical advantages. This clinical evidence base is a central element of how the company positions its technology within the urology field.

Aquablation therapy and clinical applications

Company disclosures explain that Aquablation therapy is an ultrasound-guided, robotic-assisted, heat-free waterjet treatment for BPH. Real-time ultrasound imaging provides a multi-dimensional view of the prostate, enabling surgeons to plan treatment tailored to each patient’s anatomy. Surgeons can specify which areas of the prostate to remove while preserving structures that control erectile function, ejaculatory function, and continence. Once the treatment plan is mapped, the robotic system executes the resection of prostate tissue in a controlled and predictable fashion.

In addition to BPH, PROCEPT BioRobotics is involved in clinical research evaluating Aquablation therapy for localized prostate cancer. The WATER IV Prostate Cancer (PCa) Trial, described as an FDA investigational device exemption (IDE) study, compares Aquablation therapy with radical prostatectomy for men with Grade Group 1 to 3 localized prostate cancer. The trial is designed to evaluate and compare safety and efficacy between these two surgical approaches.

Product portfolio: AQUABEAM and HYDROS Robotic Systems

Across multiple company communications, PROCEPT BioRobotics highlights two main robotic platforms:

• AQUABEAM Robotic System – A robotic system used to perform Aquablation therapy for BPH, combining real-time ultrasound imaging with a robotically controlled waterjet.
• HYDROS Robotic System – Described by the company as the only AI-powered robotic technology that delivers Aquablation therapy. The HYDROS system is positioned as a key driver of system placements and procedure growth.

These systems are used in minimally invasive urologic surgery, with an initial and ongoing emphasis on treating BPH and, in clinical studies, localized prostate cancer. Company financial updates reference revenue from U.S. systems, rentals, handpieces, and consumables, as well as international revenue, indicating that the business model includes both capital equipment and recurring procedure-related components.

Clinical evidence and market context in BPH

PROCEPT BioRobotics emphasizes that BPH is a prevalent condition and that Aquablation therapy is intended to address lower urinary tract symptoms associated with BPH while aiming to preserve sexual and urinary function. The company notes that Aquablation therapy is designed to deliver outcomes that are independent of prostate size and shape or surgeon experience, which it presents as a key clinical and operational advantage.

The company also highlights a "significant and growing" body of clinical evidence, referencing more than 150 peer-reviewed publications. These publications are cited as supporting both the benefits and clinical advantages of Aquablation therapy, including its safety profile, durability of symptom relief, and functional outcomes. In addition, PROCEPT BioRobotics is sponsoring the WATER IV prostate cancer trial, which is intended to explore whether Aquablation therapy can serve as a treatment option for localized prostate cancer, potentially changing how urologists treat this disease if trial results support its use.

Regulatory and reimbursement developments

In company news, PROCEPT BioRobotics reports that Aquablation therapy has been assigned a Category I Current Procedural Terminology (CPT) code in the Medicare Proposed Physician Fee Schedule, with effectiveness described as beginning January 1, 2026, subject to the final rule. This transition from a Category III to a Category I CPT code is described by the company as a major milestone that recognizes the clinical value and widespread use of Aquablation therapy. The company states that the Category I code is expected to support surgeon adoption and broaden patient access by establishing a more standard reimbursement framework within Medicare.

Geographic reach and revenue mix

According to earlier descriptive information, PROCEPT BioRobotics generates a majority of its revenue from the United States and also has a presence in markets outside the U.S. More recent financial press releases break out U.S. and international revenue, indicating that the company’s installed base of robotic systems and procedure volumes are growing in both domestic and international markets. The company also reports an installed base of hundreds of robotic systems in the U.S., reflecting ongoing adoption of its technology by hospitals and urology practices.

Stock listing and regulatory filings

PROCEPT BioRobotics Corporation’s common stock trades on The Nasdaq Global Market under the ticker symbol PRCT, as disclosed in its Form 8-K filings. The company files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K covering financial results, executive compensation matters, and other material events.

Position within surgical and medical instrument manufacturing

Within the broader surgical and medical instrument manufacturing industry, PROCEPT BioRobotics focuses specifically on robotic systems and associated technologies for urologic surgery. Its emphasis on BPH and localized prostate cancer, the use of ultrasound-guided, heat-free waterjet resection, and the integration of AI-powered robotics in the HYDROS system distinguish its product offering as described in company materials. The combination of capital equipment, procedure-enabling disposables, and clinical evidence-driven adoption shapes the company’s role in the urology segment of the medical device market.

FAQs about PROCEPT BioRobotics (PRCT)

• What does PROCEPT BioRobotics Corporation do?
  PROCEPT BioRobotics is a surgical robotics company focused on urology. It develops, manufactures, and sells the AQUABEAM and HYDROS Robotic Systems, which are used to deliver Aquablation therapy for benign prostatic hyperplasia and are being studied for localized prostate cancer.
• What is Aquablation therapy?
  Aquablation therapy is described by the company as the first and only ultrasound-guided, robotic-assisted, heat-free waterjet treatment for BPH. It uses real-time ultrasound imaging and a robotically controlled waterjet to remove prostate tissue in a precise and targeted manner.
• How is the HYDROS Robotic System different?
  PROCEPT BioRobotics states that the HYDROS Robotic System is the only AI-powered robotic technology that delivers Aquablation therapy. It is highlighted as a key platform for system placements and procedure growth in the company’s financial updates.
• Which medical conditions does PROCEPT BioRobotics focus on?
  The company focuses primarily on benign prostatic hyperplasia (BPH) and lower urinary tract symptoms due to BPH. It is also sponsoring the WATER IV Prostate Cancer Trial to evaluate Aquablation therapy for men with Grade Group 1 to 3 localized prostate cancer.
• What clinical evidence supports Aquablation therapy?
  According to company disclosures, PROCEPT BioRobotics has developed a significant and growing body of clinical evidence, with over 150 peer-reviewed publications supporting the benefits and clinical advantages of Aquablation therapy.
• How does Aquablation therapy aim to preserve sexual and urinary function?
  Company descriptions explain that real-time ultrasound imaging allows surgeons to map which areas of the prostate to remove while preserving anatomy that controls erectile function, ejaculatory function, and continence. The robotic system then executes the planned resection.
• Where does PROCEPT BioRobotics generate its revenue?
  Descriptive information indicates that PROCEPT BioRobotics generates a majority of its revenue from the United States and also has a presence in markets outside the U.S. Financial press releases further distinguish between U.S. and international revenue.
• On which exchange is PRCT listed?
  PROCEPT BioRobotics Corporation’s common stock is listed on The Nasdaq Global Market under the ticker symbol PRCT, as stated in its Form 8-K filings.
• What is the significance of the Category I CPT code for Aquablation therapy?
  The company reports that Aquablation therapy has been assigned a Category I CPT code in the Medicare Proposed Physician Fee Schedule, which it describes as a major milestone that recognizes clinical value and widespread use and is expected to support surgeon adoption and patient access, subject to final rulemaking.
• How can investors learn more about PROCEPT BioRobotics’ performance?
  Investors can review the company’s SEC filings, including Forms 10-K, 10-Q, and 8-K, which contain information on financial results, risk factors, and other material events. The company also hosts earnings conference calls and webcasts for its quarterly financial results.